Ultragenyx Pharmaceutical Inc. (RARE) News
Filter RARE News Items
RARE News Results
|Loading, please wait...|
RARE News Highlights
- RARE's 30 day story count now stands at 2.
- Over the past 14 days, the trend for RARE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RARE News From Around the Web
Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Eric Crombez, M.D. Eric Crombez, M.D. NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in an Orphan Neuro Panel at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET. The live and archived
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2022 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2022 Financial Results Conference Call. It is now my pleasure to turn the call over to Joshua Higa, Executive Director and Head of Investor Relations. Joshua Higa: Thank you. We […]
12 Stocks To Sell According to Motley Fool
In this article, we will be looking at 12 stocks to sell according to Motley Fool. To skip our detailed analysis of current market dynamics heading into 2023, you can go directly to see the 5 Stocks To Sell According to Motley Fool. Motley Fool Asset Management focuses on high-quality growth companies, and it is constantly […]
Ultragenyx Pharmaceutical Full Year 2022 Earnings: In Line With Expectations
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) Full Year 2022 Results Key Financial Results Revenue: US$363.3m (up 3.4% from...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) by...
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Year-end 2022 cash balance of $896.7 million and 2023 guidance for Net Cash used in Operations expected to be less than $400 million NOVATO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ultr
Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 16, 2023, at 5:00 p.m. ET to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2022. The live and replayed webcast of the call